Abstracts Archive - Page 1302 of 2607 - ACR Meeting Abstracts

Abstract Number: 1735 • 2018 ACR/ARHP Annual Meeting
Diagnostic Accuracy of MR Angiography in a Cohort with Systemic Sclerosis Compared to Other Rheumatic Diseases with Acral Hypoperfusion
Diana Dan^1,2, Simon Saner¹, Andrea D. Gloor^1,3, Harald Bonel⁴, Jennifer L. Cullmann⁴ and Peter M. Villiger¹, ¹Department of Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ²Service of Rheumatology, Lausanne University Hospital, Lausanne, Switzerland, ³Dermatology, Inselspital, University Hospital of Bern, Bern, Switzerland, ⁴Institute of Diagnostic, Interventional and Pediatric Radiology, Inselspital, University Hospital of Bern, Bern, Switzerland
Background/Purpose: Vasculopathy is a major feature of systemic sclerosis (SSc). It leads to intimal proliferation and adventitial fibrosis of small and large arterial blood vessels.…
Abstract Number: 1736 • 2018 ACR/ARHP Annual Meeting
Incidence and Risk Factors for Gangrene in Patients with Systemic Sclerosis from the Eustar Cohort
Carina Mihai^1,2, Oliver Distler¹, Ana Maria Gheorghiu^2,3, Paul Iulian Constantin², Rucsandra Dobrota^1,2, Suzana Jordan⁴, Vanessa Smith⁵, Eric Hachulla⁶, Joerg C. Henes⁷, Elise Siegert⁸, Serena Vettori⁹, Ulf Müller-Ladner¹⁰, Marco Matucci-Cerinic¹¹ and Yannick Allanore¹², ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Cantacuzino Hospital, Bucharest, Romania, ⁴Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, ⁷Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ⁸Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁹Rheumatology Unit, Department of Internal and Experimental Medicine University of Campania "Luigi Vanvitelli", Napoli, Italy, ¹⁰Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Bad Nauheim, Germany, ¹¹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹²Cochin Hospital, Paris Descartes University, Paris, France, Paris, France
Background/Purpose: In patients with systemic sclerosis (SSc), peripheral vasculopathy can promote critical ischemia and gangrene that are very severe complications with potential life-threatening consequences. Recently…
Abstract Number: 1737 • 2018 ACR/ARHP Annual Meeting
Multiplexed Autoantibody Profiles in a Systemic Sclerosis Clinical Trial Comparing Autologous Hematopoietic Stem Cell Transplantation and Cyclophosphamide
Paul J. Utz¹ and Burcu Ayoglu², ¹Medicine, Stanford University School of Medicine, Stanford, CA, ²Medicine, Stanford University, STANFORD, CA
Background/Purpose: In a randomized, open-label, phase II clinical trial (SCOT, Scleroderma: Cyclophosphamide or Transplantation)1, subjects were randomly assigned to treatment with myeloablative CD34+ selected autologous…
Abstract Number: 1738 • 2018 ACR/ARHP Annual Meeting
Detect Outperforms Echocardiography Based Screening Guidelines for Early Detection of Systemic Sclerosis Associated Pulmonary Arterial Hypertension
Amber Young¹, Victor M. Moles^2,3, Vivek Nagaraja¹, Dharshan Vummidi⁴, Scott H. Visovatti³, Vallerie McLaughlin³ and Dinesh Khanna¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Hospital Jose Maria Cullen, Santa Fe, Argentina, ³Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁴Department of Radiology, University of Michigan, Ann Arbor, MI
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in patients with systemic sclerosis (SSc). Active screening can detect SSc-PAH earlier and may…
Abstract Number: 1739 • 2018 ACR/ARHP Annual Meeting
What Do Patient Reported Outcomes for Routine Monitoring of Gastrointestinal Tract Symptoms in a Systemic Sclerosis Center Tell Us about Clinical Features of Potential Small Intestinal Bacterial Overgrowth?
Jessica Zhu¹, Craig Gale², Joshua Biber³, Mandana Nikpour⁴, Murray Baron⁵ and Tracy M. Frech⁶, ¹School of Medicine, University of Utah, Salt Lake City, UT, ²Bioinformatics, University of Utah, Salt Lake City, UT, ³University of Utah, Salt Lake City, UT, ⁴The University of Melbourne, Melbourne, Australia, Melbourne, Australia, ⁵Department of Medicine, McGill University, Montreal, QC, Canada, ⁶Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: The implementation of patient reported outcome measures (PROMs) is increasingly recognized as a critical aspect of clinical practice. The use of gastrointestinal (GI) PROMs…
Abstract Number: 1740 • 2018 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series
Judit Lluch¹, Ivan Castellvi², J Alegre³, Pablo Juárez¹, Joan Miquel Nolla¹ and Francisco Javier Narváez⁴, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Santa Creu i San Pau, Barcelona, Spain, ³Rheumatology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁴Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain
Background/Purpose: To evaluate the efficacy and safety of TCZ as as a rescue therapy in patients with refractory scleroderma-associated interstitial lung disease (SSc-ILD). Methods: We…
Abstract Number: 1741 • 2018 ACR/ARHP Annual Meeting
Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis
Svetlana I. Nihtyanova¹, Alper Sari², Voon H. Ong³ and Christopher P. Denton⁴, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Division of Medicine, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: Although severity of skin involvement and change in skin thickness over time vary substantially between patients with diffuse cutaneous systemic sclerosis (dcSSc), for the…
Abstract Number: 1742 • 2018 ACR/ARHP Annual Meeting
Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis
Svetlana I. Nihtyanova¹, Alper Sari², Anna Leslie³, Voon H. Ong⁴ and Christopher P. Denton⁵, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Division of Medicine, University College London, London, United Kingdom, ⁵University College London, London, United Kingdom
Background/Purpose: Pulmonary fibrosis (PF) is a leading cause of disease-related death in SSc patients. Some studies suggest that the timing of PF development differs between…
Abstract Number: 1743 • 2018 ACR/ARHP Annual Meeting
Serum Markers Potentially Associated with PAH in Systemic Sclerosis; A Targeted Screening Approach
Anders Heiervang Tennøe¹, Håvard Fretheim², Oyvind Midtvedt², Torhild Garen², Thor Ueland³, Pål Aukrust², Arne K Andreassen², Einar Gude², Øyvind Molberg² and Anna-Maria Hoffmann-Vold², ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Research Institute of Internal Medicine Research, Oslo University Hospital, Oslo, Norway
Background/Purpose: Pulmonary arterial hypertension (PAH) is a feared complication in systemic sclerosis (SSc). Detection of PAH at a preclinical stage is important as early diagnosis…
Abstract Number: 1744 • 2018 ACR/ARHP Annual Meeting
Prognostic Value of Right Heart Involvement in Systemic Sclerosis:Not Only Pulmonary Arterial Hypertension
Luna Gargani¹, Cosimo Bruni², Antonella Moreo³, Laura Belloli³, Silvia Bellando-Randone², Oscar Massimiliano Epis³, Francesco Ferrara⁴, Olga Vriz⁵, Eduardo Bossone⁶, Petar M. Seferovic⁷, Daniel E. Furst⁸ and Marco Matucci-Cerinic⁹, ¹Institute of Clinical Physiology, Consiglio Nazionale delle Ricerche (CNR), Pisa, Italy, ²Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ³Niguarda Ca’ Granda Hospital, Milan, Italy, ⁴"Cava de' Tirreni and Amalfi Coast", University Hospital, Salerno, Italy, ⁵King Faisal Hospital, Riyadh, Saudi Arabia, ⁶Cardarelli Hospital, Naples, Italy, ⁷Department of Cardiology, , Clinical Center of Serbia and Belgrade University School of Medicine, Belgrade, Serbia, ⁸University of California Los Angeles, Los Angeles, CA, ⁹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Background/Purpose: In SSc, cardiac dysfunction is associated with poor prognosis. Right ventricular involvement is frequently secondary to PAH. Echocardiography is the routine imaging tool to…
Abstract Number: 1745 • 2018 ACR/ARHP Annual Meeting
Efficacy of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) Treatments According to the Type of Manifestations Based on Analysis of 376 Patients
Matthias Papo¹, Giacomo Emmi², Franco Schiavon³, Matthieu Groh⁴, Maria-Letizia Urban², Chiara Marvisi⁵, Jean-Emmanuel Kahn⁴, Alberto Sinico⁶, Maxime Samson⁷, Pascal Cohen¹, Xavier Puéchal¹, Luc Mouthon¹, Loïc Guillevin¹, Augusto Vaglio⁵ and Benjamin Terrier⁸, ¹Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁴Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, ⁵Nephrology Unit, Parma University Hospital, Parma, Italy, ⁶UOS di Immunologia Clinica e UOC di Nefrologia, Azienda Ospedaliera San Carlo Borromeo, Milan, Italy, ⁷Department of Internal Medicine and Clinical Immunology, François-Mitterrand Teaching Hospital, University of Bourgogne-Franche-Comté, Dijon, France, ⁸Department of Internal Medicine, Centre de Référence pour les Maladies Auto-immunes Rares, Paris, France, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg–Strauss) is a small-vessel necrotizing vasculitis characterized by blood and tissue eosinophilia and asthma. Glucocorticoids (GCs) represent the cornerstone…
Abstract Number: 1746 • 2018 ACR/ARHP Annual Meeting
Impact of Interstitial Lung Disease on the Long-Term Survival in 76 Japanese Patients with Microscopic Polyangiitis
Hiromi Matsushita¹, Yoshioki Yamasaki², Yukiko Takakuwa³, Hidehiro Yamada⁴ and Kimito Kawahata³, ¹Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan
Background/Purpose: ANCA-associated vasculitis including microscopic polyangiitis (MPA) involves multiple organs including lungs. Clinical characteristics and impact on long-term survival in MPA patients with interstitial lung disease (ILD) have not…
Abstract Number: 1747 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcomes of Patients with Nonsevere Eosinophilic Granulomatosis with Polyangiitis Given Azathioprine and Glucocorticoids for Remission Induction
Xavier Puéchal¹, Christian Pagnoux², Gabriel Baron³, François Lifermann⁴, Loïk Geffray⁵, Thomas Quémeneur⁶, Jean-Luc Saraux⁷, Marie Wislez⁸, Vincent Cottin⁹, Marc Ruivard¹⁰, Nicolas Limal¹¹, Achille Aouba¹², Bernard Bonnotte¹³, Antoine Neel¹⁴, Christian Agard¹⁵, Pascal Cohen¹⁶, Benjamin Terrier¹⁷, Claire Le Jeunne¹⁷, Luc Mouthon¹, Philippe Ravaud³ and Loïc Guillevin for the French Vasculitis Study Group¹⁷, ¹Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ²Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ³Paris Hôtel Dieu, Paris, France, ⁴Dax, Dax, France, ⁵Lisieux, Lisieux, France, ⁶Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, ⁷Eaubonne, Eaubonne, France, ⁸Paris Tenon, Paris, Gambia, ⁹Lyon Louis Pradel, Lyon, France, ¹⁰Clermont-Ferrand, Clermont Ferrand, France, ¹¹Créteil Henri Mondor, Créteil, France, ¹²Caen, Caen, France, ¹³Dijon, Dijon, France, ¹⁴Medecine Interne, Nantes Hôtel Dieu, Nantes, France, ¹⁵Nantes Hôtel Dieu, Nantes, France, ¹⁶Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁷National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: At month 24 (M24), CHUSPAN2-trial patients with nonsevere eosinophilic granulomatosis with polyangiitis (EGPA), who received 1 yr of azathioprine (AZA) and glucocorticoids (GC) as…
Abstract Number: 1748 • 2018 ACR/ARHP Annual Meeting
Interstitial Lung Disease in ANCA-Positive Vasculitis Patients
Andy Abril¹, Minkyung Kwon,², Isabel Mira-Avendano³, Carlos Rojas⁴ and Andras Khoor⁵, ¹Rheumatology, Mayo Clinic Florida, Jacksonville, FL, ²Pulmonary and Critical Care, Mayo Clinic, Jacksonville, FL, ³Pulmonary and Critical Care, Mayo Clinic Florida, Jacksonville, FL, ⁴Radiology, Mayo Clinic, Jacksonville, FL, ⁵Pathology, Mayo Clinic, Jacksonville, FL
Background/Purpose: Rarely, ANCA-positive vasculitis patients are found to have interstitial lung disease (ILD). Clinical characteristics and prognosis are not well known in these patients. The…
Abstract Number: 1749 • 2018 ACR/ARHP Annual Meeting
Long-Term Renal Outcome in Pulmonary-Limited Microscopic Polyangiitis
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Patients with pulmonary-renal or renal-limited microscopic polyangiitis (MPA) frequently manifested with rapidly progressive glomerular nephritis resulting in chronic renal failure if clinical response to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].